Kalaris Therapeutics Inc
KLRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$65.65M
Close$
$6.33
46.5% upside
Current Fair Value
46.5% upsideUndervalued by 46.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $65.65 Million |
|---|---|
| Enterprise Value | $32.63 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.85 |
| Beta | 0.19 |
| Outstanding Shares | 23,723,618 |
Return
| Return on Equity | -64.32% |
|---|---|
| Return on Assets | -40.16% |
| Return on Invested Capital | -46.82% |
Valuation & Multiples
| P/E Ratio | -1.63 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 2.16 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.69 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 78.31%▼ 0.26% |
|---|---|
| Total Invested | $107.18M▼ 29.43% |
| Investors Holding | 58▲ 7.00% |
ESG Score
No data
About Kalaris Therapeutics Inc
14 employees
CEO: Mr. Andrew Oxtoby Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.